{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:41:49Z","timestamp":1791340909204,"version":"4.3.1"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T00:00:00Z","timestamp":1630368000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["IKNL2014-6838"],"award-info":[{"award-number":["IKNL2014-6838"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Epidemiology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.canep.2021.102008","type":"journal-article","created":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T02:00:26Z","timestamp":1631152826000},"page":"102008","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Clinicopathologic predictors of early relapse in advanced epithelial ovarian cancer: development of prediction models using nationwide data"],"prefix":"10.1016","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0226-5200","authenticated-orcid":false,"given":"Sherin A.","family":"Said","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reini W.","family":"Bretveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1753-0652","authenticated-orcid":false,"given":"Hendrik","family":"Koffijberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabe S.","family":"Sonke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1305-9541","authenticated-orcid":false,"given":"Roy F.P.M.","family":"Kruitwagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne A.","family":"de Hullu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"van Altena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Siesling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maaike A.","family":"van der Aa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.canep.2021.102008_bib0005","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"issue":"6","key":"10.1016\/j.canep.2021.102008_bib0010","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.canep.2021.102008_bib0015","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-016-0548-9","article-title":"Prediction of chemo-response in serous ovarian cancer","volume":"15","author":"Gonzalez Bosquet","year":"2016","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.canep.2021.102008_bib0020","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11010119","article-title":"Platinum resistance in ovarian cancer: role of DNA repair","volume":"11","author":"Damia","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.canep.2021.102008_bib0025","doi-asserted-by":"crossref","first-page":"R303","DOI":"10.1530\/ERC-17-0336","article-title":"Biomarkers of platinum resistance in ovarian cancer: what can we use to improve treatment","volume":"25","author":"van Zyl","year":"2018","journal-title":"Endocr. Relat. Cancer"},{"issue":"1","key":"10.1016\/j.canep.2021.102008_bib0030","doi-asserted-by":"crossref","DOI":"10.1186\/1756-9966-30-91","article-title":"Platinum resistance in breast and ovarian cancer cell lines","volume":"30","author":"Eckstein","year":"2011","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.canep.2021.102008_bib0035","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1158\/1078-0432.CCR-04-1673","article-title":"Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy","volume":"11","author":"Hartmann","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.canep.2021.102008_bib0040","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1021\/acs.jproteome.5b01129","article-title":"Predicting ovarian cancer patients\u2019 clinical response to platinum-based chemotherapy by their tumor proteomic signatures","volume":"15","author":"Yu","year":"2016","journal-title":"J. Proteome Res."},{"issue":"36","key":"10.1016\/j.canep.2021.102008_bib0045","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000004797","article-title":"Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer","volume":"95","author":"Luo","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.canep.2021.102008_bib0050","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ygyno.2013.01.009","article-title":"Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma","volume":"129","author":"Rauh-Hain","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.canep.2021.102008_bib0055","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ejogrb.2019.07.010","article-title":"Perioperative change in CA125 is an independent prognostic factor for improved clinical outcome in advanced ovarian cancer","volume":"240","author":"Timmermans","year":"2019","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"issue":"29","key":"10.1016\/j.canep.2021.102008_bib0060","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1093\/eurheartj\/ehu207","article-title":"Towards better clinical prediction models: seven steps for development and an ABCD for validation","volume":"35","author":"Steyerberg","year":"2014","journal-title":"Eur. Heart J."},{"issue":"3","key":"10.1016\/j.canep.2021.102008_bib0065","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ygyno.2014.02.038","article-title":"\u201cPlatinum resistant\u201d ovarian cancer: what is it, who to treat and how to measure benefit?","volume":"133","author":"Davis","year":"2014","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"10.1016\/j.canep.2021.102008_bib0070","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/IGC.0b013e3181dd0110","article-title":"Prognostic relevance of uncommon ovarian histology in women with stage III\/IV epithelial ovarian cancer","volume":"20","author":"Mackay","year":"2010","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"Suppl 3","key":"10.1016\/j.canep.2021.102008_bib0075","doi-asserted-by":"crossref","first-page":"S971","DOI":"10.1245\/s10434-015-4623-z","article-title":"Neoadjuvant chemotherapy followed by interval debulking surgery and the risk of platinum resistance in epithelial ovarian cancer","volume":"22","author":"da Costa","year":"2015","journal-title":"Ann. Surg. Oncol."},{"issue":"12","key":"10.1016\/j.canep.2021.102008_bib0080","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.1245\/s10434-013-3091-6","article-title":"Timing and pattern of recurrence in ovarian cancer patients with high tumor dissemination treated with primary debulking surgery versus neoadjuvant chemotherapy","volume":"20","author":"Petrillo","year":"2013","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.canep.2021.102008_bib0085","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ejogrb.2018.02.029","article-title":"Neoadjuvant chemotherapy or primary debulking surgery in FIGO IIIC and IV patients; results from a survey study in the Netherlands","volume":"223","author":"Timmermans","year":"2018","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"issue":"3","key":"10.1016\/j.canep.2021.102008_bib0090","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11030416","article-title":"Tailoring ovarian cancer treatment: implications of BRCA1\/2 mutations","volume":"11","author":"Madariaga","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"14","key":"10.1016\/j.canep.2021.102008_bib0095","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/jama.2011.1456","article-title":"Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer","volume":"306","author":"Yang","year":"2011","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.canep.2021.102008_bib0100","doi-asserted-by":"crossref","DOI":"10.1186\/s13048-019-0484-6","article-title":"Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status","volume":"12","author":"Gadducci","year":"2019","journal-title":"J. Ovarian Res."},{"key":"10.1016\/j.canep.2021.102008_bib0105","article-title":"Universal tumor DNA BRCA1\/2 testing of ovarian cancer: prescreening PARPi treatment and genetic predisposition","author":"Vos","year":"2019","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.canep.2021.102008_bib0110","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ejca.2016.03.009","article-title":"Germline BRCA1\/2 mutation testing is indicated in every patient with epithelial ovarian cancer: a systematic review","volume":"61","author":"Arts-de Jong","year":"2016","journal-title":"Eur. J. Cancer"},{"issue":"17","key":"10.1016\/j.canep.2021.102008_bib0115","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.7150\/jca.21362","article-title":"The effect of CA125 nadir level on survival of advanced-stage epithelial ovarian carcinoma after interval debulking surgery","volume":"8","author":"Zeng","year":"2017","journal-title":"J. Cancer"}],"container-title":["Cancer Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877782121001259?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877782121001259?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T05:29:55Z","timestamp":1761802195000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1877782121001259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":23,"alternative-id":["S1877782121001259"],"URL":"https:\/\/doi.org\/10.1016\/j.canep.2021.102008","relation":{},"ISSN":["1877-7821"],"issn-type":[{"value":"1877-7821","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinicopathologic predictors of early relapse in advanced epithelial ovarian cancer: development of prediction models using nationwide data","name":"articletitle","label":"Article Title"},{"value":"Cancer Epidemiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canep.2021.102008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102008"}}